Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings,...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Radiology
2025-01-01
|
Series: | Journal of the Korean Society of Radiology |
Subjects: | |
Online Access: | https://doi.org/10.3348/jksr.2024.0147 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832576361826353152 |
---|---|
author | Jimin Kim Eunhee Kim Mina Park Yun Jung Bae Chong Hyun Suh Sung-Hye You Younghee Yim Ho-Joon Lee Jin Wook Choi Se Won Oh Won-Jin Moon |
author_facet | Jimin Kim Eunhee Kim Mina Park Yun Jung Bae Chong Hyun Suh Sung-Hye You Younghee Yim Ho-Joon Lee Jin Wook Choi Se Won Oh Won-Jin Moon |
author_sort | Jimin Kim |
collection | DOAJ |
description | The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi
®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging
abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings, the
Korean Society of Neuroradiology (KSNR) and the Age and Neurodegeneration Imaging (ANDI) Study
Group proposed MRI protocol recommendations on essential MR sequences, MRI acquisition parameters,
timing and condition of MRI examinations, and essential details to provide a scientific basis for
maximizing the safety and efficacy of AD treatment. A customized, standardized MRI protocol focusing
on Korea’s healthcare environment can improve ARIA management and ensure patient safety through
early detection of potential anti-amyloid therapy side effects, thereby enhancing treatment quality. |
format | Article |
id | doaj-art-b62d7fa0511743bf9e6c06f0e29ebddf |
institution | Kabale University |
issn | 2951-0805 |
language | English |
publishDate | 2025-01-01 |
publisher | The Korean Society of Radiology |
record_format | Article |
series | Journal of the Korean Society of Radiology |
spelling | doaj-art-b62d7fa0511743bf9e6c06f0e29ebddf2025-01-31T07:16:06ZengThe Korean Society of RadiologyJournal of the Korean Society of Radiology2951-08052025-01-018613444https://doi.org/10.3348/jksr.2024.0147Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI ProtocolJimin KimEunhee KimMina ParkYun Jung BaeChong Hyun SuhSung-Hye YouYounghee YimHo-Joon LeeJin Wook ChoiSe Won OhWon-Jin MoonThe introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings, the Korean Society of Neuroradiology (KSNR) and the Age and Neurodegeneration Imaging (ANDI) Study Group proposed MRI protocol recommendations on essential MR sequences, MRI acquisition parameters, timing and condition of MRI examinations, and essential details to provide a scientific basis for maximizing the safety and efficacy of AD treatment. A customized, standardized MRI protocol focusing on Korea’s healthcare environment can improve ARIA management and ensure patient safety through early detection of potential anti-amyloid therapy side effects, thereby enhancing treatment quality.https://doi.org/10.3348/jksr.2024.0147alzheimer’s diseaseamyloid-related imaging abnormalitiesanti-amyloid monoclonal antibodiesmagnetic resonance imagingmonitoring |
spellingShingle | Jimin Kim Eunhee Kim Mina Park Yun Jung Bae Chong Hyun Suh Sung-Hye You Younghee Yim Ho-Joon Lee Jin Wook Choi Se Won Oh Won-Jin Moon Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol Journal of the Korean Society of Radiology alzheimer’s disease amyloid-related imaging abnormalities anti-amyloid monoclonal antibodies magnetic resonance imaging monitoring |
title | Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol |
title_full | Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol |
title_fullStr | Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol |
title_full_unstemmed | Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol |
title_short | Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol |
title_sort | amyloid related imaging abnormalities in anti amyloid monoclonal antibody therapy for alzheimer s disease expert recommendation for standard mri protocol |
topic | alzheimer’s disease amyloid-related imaging abnormalities anti-amyloid monoclonal antibodies magnetic resonance imaging monitoring |
url | https://doi.org/10.3348/jksr.2024.0147 |
work_keys_str_mv | AT jiminkim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT eunheekim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT minapark amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT yunjungbae amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT chonghyunsuh amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT sunghyeyou amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT youngheeyim amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT hojoonlee amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT jinwookchoi amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT sewonoh amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol AT wonjinmoon amyloidrelatedimagingabnormalitiesinantiamyloidmonoclonalantibodytherapyforalzheimersdiseaseexpertrecommendationforstandardmriprotocol |